Compare Stocks

→ This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$1.71 +0.6%	$1.69	$0.77 ▼ $14.00	$6.93M	1.48	5.12 million shs	142,940 shs
BIXT Bioxytran	$0.13 -14.4%	$0.12	$0.07 ▼ $0.54	$21.75M	-0.83	101,148 shs	212,949 shs
ITRM Iterum Therapeutics	$1.55 -1.9%	$1.51	$0.62 ▼ $2.50	$25.47M	2.36	507,395 shs	35,939 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	-10.53%	-24.11%	0.00%	+34.92%	-81.62%
BIXT Bioxytran	+3.55%	+24.79%	+26.96%	+8.15%	-69.26%
ITRM Iterum Therapeutics	+1.94%	+8.97%	-1.25%	-20.20%	+46.30%

One trade. One ticker. One week. (Ad)

Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?

Well, then you should click here to see this free training.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	0.7674 of 5 stars	0.0	5.0	0.0	0.0	2.5	0.8	0.6
BIXT Bioxytran	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	0.8733 of 5 stars	3.5	2.0	0.0	0.0	0.6	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A
BIXT Bioxytran	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	3.00	Buy	$6.00	287.10% Upside

Current Analyst Ratings

Latest ITRM, BIXT, and ADIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/1/2024	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/6/2024	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
2/7/2024	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$6.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$2.46 per share	N/A
BIXT Bioxytran	N/A	N/A	N/A	N/A	($0.01) per share	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.48) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$5.12M	-$5.72	N/A	N/A	N/A	N/A	-250.52%	-183.24%	5/10/2024 (Estimated)
BIXT Bioxytran	-$4.28M	-$0.03	N/A	∞	N/A	N/A	N/A	-2,861.84%	N/A
ITRM Iterum Therapeutics	-$38.37M	-$2.97	N/A	N/A	N/A	N/A	-664.00%	-87.64%	5/10/2024 (Estimated)

Latest ITRM, BIXT, and ADIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/28/2024	Q4 2023	ITRM Iterum Therapeutics	-$1.02	-$0.94	+$0.08	-$0.94	N/A	N/A
3/22/2024	Q4 2023	BIXT Bioxytran	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIXT Bioxytran	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	4.90	4.90
BIXT Bioxytran	N/A	0.01	0.01
ITRM Iterum Therapeutics	3.63	1.89	1.89

Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
BIXT Bioxytran	N/A
ITRM Iterum Therapeutics	9.21%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	14.47%
BIXT Bioxytran	70.00%
ITRM Iterum Therapeutics	5.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	16	4.05 million	3.47 million	No Data
BIXT Bioxytran	2	173.98 million	52.20 million	Not Optionable
ITRM Iterum Therapeutics	14	16.43 million	15.54 million	Not Optionable

ITRM, BIXT, and ADIL Headlines

Source	Headline
	Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript finance.yahoo.com - April 2 at 10:27 AM
	Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript seekingalpha.com - March 30 at 6:45 PM
	Q4 2023 Iterum Therapeutics PLC Earnings Call finance.yahoo.com - March 29 at 2:40 AM
	Iterum Therapeutics PLC: Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results finanznachrichten.de - March 28 at 11:34 AM
	Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results globenewswire.com - March 28 at 7:00 AM
	Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 globenewswire.com - March 21 at 4:30 PM
	Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat globenewswire.com - March 15 at 8:00 AM
	EQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations markets.businessinsider.com - March 12 at 10:42 AM
	Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up zacks.com - March 7 at 9:00 AM
	Iterum Therapeutics Provides Business Update finance.yahoo.com - March 6 at 7:38 PM
	Iterum Therapeutics PLC (ITRM) investing.com - February 28 at 7:36 AM
	Iterum Therapeutics (ITRM) Price Target Increased by 550.00% to 6.63 msn.com - February 24 at 2:19 AM
	Steven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLC finance.yahoo.com - February 1 at 4:09 PM
	Iterum Shareholders Reject Board’s Share Issuance Proposal msn.com - February 1 at 12:05 AM
	Iterum Therapeutics Announces Triumph in Phase 3 uUTI Trial msn.com - January 31 at 7:49 AM
	Why Iterum Therapeutics Stock Is Trending Today msn.com - January 30 at 4:48 PM
	Iterum meets main goal in late trial for uUTI treatment with oral sulopenem msn.com - January 30 at 4:48 PM
	Iterum Therapeutics's Late-stage REASSURE Trial Successfully Met Primary Endpoint markets.businessinsider.com - January 30 at 4:48 PM
	Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint marketwatch.com - January 30 at 9:45 AM
	Iterum Therapeutics Shares Surge on Positive UTI Drug Trial Results marketwatch.com - January 30 at 9:45 AM
	Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections finance.yahoo.com - January 30 at 9:45 AM
	The Potential Rise in the Price of Iterum Therapeutics Plc (ITRM) following insiders activity knoxdaily.com - January 1 at 8:29 AM
	Insiders Buying Iterum Therapeutics And 3 Other Stocks Under $3 msn.com - December 28 at 1:31 PM
	Iterum Therapeutics director discloses purchase of 20K shares msn.com - November 29 at 1:43 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adial Pharmaceuticals

NASDAQ:ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Bioxytran

OTCMKTS:BIXT

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Iterum Therapeutics

NASDAQ:ITRM

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial